Drugs / PF-07054894
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07009353 | Jun → Aug 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06327880 | May → Jul 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05549323 | Nov 2022 → Nov 2025 | ulcerative colitis | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04388878 | Jul 2020 → Jun 2022 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07054894 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07009353 ↗ |
| Modality | Small molecule | — CHEMBL6068520 ↗ |
| Route | Oral | “Oral PF-07054894” NCT05549323 ↗ |